Chronic Spontaneous Urticaria Market Growth Projections 2024-2034: DelveInsight Analysis

DelveInsight's "Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Spontaneous Urticaria, historical and forecasted epidemiology as well as the Chronic Spontaneous Urticaria market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Spontaneous Urticaria market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Spontaneous Urticaria Market Forecast
https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Chronic Spontaneous Urticaria Market Report:
• The Chronic Spontaneous Urticaria market size was valued USD 2,173 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In July 2025, Jasper Therapeutics, Inc. (Nasdaq: JSPR), a clinical-stage biotech developing briquilimab, a novel KIT (CD117)-targeting antibody therapy for mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), has shared updated data from its BEACON Phase 1b/2a study of subcutaneous briquilimab in adults with CSU, along with a program update. Treatment with briquilimab in the 240mg and 360mg single-dose cohorts achieved rapid and deep disease control, with 8 of 9 participants (89%) attaining a complete response and 7 of 9 (78%) showing clinical response by week 2. Participants rolling over into the open-label extension at 180mg Q8W demonstrated strong efficacy, with 8 of 11 (73%) achieving a complete response by 12 weeks.
• In March 2025, Results from the Phase III REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) trials demonstrate that remibrutinib effectively alleviates symptoms of chronic spontaneous urticaria (CSU) in patients who do not respond to second-generation H1-antihistamines. The studies, published in The New England Journal of Medicine, showed that the drug has a rapid onset of action, with efficacy maintained for 24 weeks, and a favorable safety profile.
• In January 2025, Jasper Therapeutics, Inc. (Nasdaq: JSPR), a clinical-stage biotechnology company developing briquilimab, a novel c-Kit (CD117) targeting antibody for mast cell-driven diseases like chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma, has announced positive preliminary data from its ongoing BEACON Phase 1b/2a study of subcutaneous briquilimab in adults with CSU. The study reported significant reductions in UAS7 scores, with an average change of -26.6 at eight weeks in the 240mg single-dose cohort. Multiple dosing regimens at or above 120mg showed reductions of over -25 points. Clinical responses were observed within a week, and patients across all dose levels (80mg, 120mg, 180mg, and 240mg) achieved Complete Responses (UAS7 = 0), with all participants in the 240mg single-dose group maintaining their response through eight weeks. The treatment demonstrated dose-dependent durability, reductions in serum tryptase, and a favorable safety profile.
• In November 2024, The FDA accepted the resubmission of the supplemental biologics license application for Dupixent, developed by Regeneron, for the treatment of chronic spontaneous urticaria in both adults and children.
• In November 2024, The U.S. Food and Drug Administration (FDA) has accepted the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat chronic spontaneous urticaria (CSU) in adults and pediatric patients aged 12 years and older, whose condition is not sufficiently managed with H1 antihistamine treatment
• In September 2024, Evommune announced the enrollment of the first patient in a Phase II trial of EVO756 in adults with CIndU.
• In 2023, the market size for chronic spontaneous urticaria in the US was estimated at USD 1,194.7 million and is projected to grow at a CAGR of 9.5% during the study period, fueled by rising disease awareness and the introduction of new therapies.
• The market size for chronic spontaneous urticaria in EU4 and the UK was estimated at approximately USD 600 million in 2023, representing around 28% of the total market revenue across the 7MM.
• In 2023, Germany held the largest market share among EU4 and the UK, with approximately USD 159.3 million, followed by France at around USD 139.5 million. Meanwhile, Spain had the smallest market, with nearly USD 78.1 million during the same year.
• In 2023, Novartis' XOLAIR led the market share among all therapies in the US, generating approximately USD 913 million in revenue. It was followed by prescription antihistamines and immunosuppressive agents, with revenues of USD 138 million and USD 123 million, respectively.
• DelveInsight's epidemiology model estimates that the total number of diagnosed prevalent cases of Chronic Spontaneous Urticaria in the 7MM was around 2.8 million in 2023, with projections for change during the forecast period (2024-2034).
• In the US, there were around 521 thousand diagnosed prevalent cases of chronic spontaneous urticaria in 2023, representing nearly 19% of the total cases across the 7MM.
• In 2023, Germany had the highest number of diagnosed prevalent cases of chronic spontaneous urticaria among the EU4 and the UK, with around 327 thousand cases, followed by France with nearly 255 thousand cases. Spain reported the lowest prevalence, with approximately 163 thousand cases.
• In 2023, Japan reported the highest number of diagnosed prevalent cases of chronic spontaneous urticaria, with around 1 million cases.
• Key Chronic Spontaneous Urticaria Companies: Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company, Genentech, GI Innovation/Yuhan, Regeneron, GlaxoSmithKline, Taiho Pharma, Glenmark Pharmaceuticals, Gossamer Bio, Kiniksa Pharmaceuticals, Mycenax Biotech, Novartis, Regeneron, Synermore Biologics, UCB Biopharma, United BioPharma, and others
• Key Chronic Spontaneous Urticaria Therapies: Ligelizumab, Remibrutinib (LOU064), Tezepelumab, CDX-0159, GI-301, Dupilumab (DUPIXENT), UB-221, MTPS9579A, Lirentelimab (AK002), TAS5315, rilzabrutinib, GDC-0853, AZD1981, Desloratadine, and others
• The Chronic Spontaneous Urticaria epidemiology based on gender analyzed that Chronic Spontaneous Urticaria is more prominent in females in comparison to males
• The Chronic Spontaneous Urticaria market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Spontaneous Urticaria pipeline products will significantly revolutionize the Chronic Spontaneous Urticaria market dynamics.

Chronic Spontaneous Urticaria Overview
Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, is a skin condition characterized by the recurrent appearance of hives (wheals or welts) and/or angioedema (swelling in deeper layers of the skin) for a duration of at least six weeks. It is termed "spontaneous" because the hives and swelling occur without an identifiable trigger or external stimulus. CSU can be associated with significant discomfort, itching, and distress, impacting the quality of life of affected individuals.

Get a Free sample for the Chronic Spontaneous Urticaria Market Report:
https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Spontaneous Urticaria Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Spontaneous Urticaria Epidemiology Segmentation:
The Chronic Spontaneous Urticaria market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Chronic Spontaneous Urticaria
• Prevalent Cases of Chronic Spontaneous Urticaria by severity
• Gender-specific Prevalence of Chronic Spontaneous Urticaria
• Diagnosed Cases of Episodic and Chronic Chronic Spontaneous Urticaria

Download the report to understand which factors are driving Chronic Spontaneous Urticaria epidemiology trends @ Chronic Spontaneous Urticaria Epidemiology Forecast
https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Spontaneous Urticaria Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Spontaneous Urticaria market or expected to get launched during the study period. The analysis covers Chronic Spontaneous Urticaria market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Spontaneous Urticaria Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Spontaneous Urticaria Therapies and Key Companies
• Ligelizumab: Novartis
• Remibrutinib (LOU064): Novartis
• Tezepelumab: Amgen
• CDX-0159: Celldex Therapeutics
• GI-301: GI Innovation
• Dupilumab (DUPIXENT): Sanofi/ Regeneron
• UB-221: United BioPharma
• MTPS9579A: Genentech
• Lirentelimab (AK002): Allakos Inc.
• TAS5315: Taiho Pharma
• rilzabrutinib: Sanofi
• GDC-0853: Genentech, Inc.
• AZD1981: AstraZeneca
• Desloratadine: Organon and Co

Discover more about therapies set to grab major Chronic Spontaneous Urticaria market share @ Chronic Spontaneous Urticaria Treatment Market
https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Spontaneous Urticaria Market Drivers
• Treatment Side Effects with Currently Available Treatment
• Economic Burden on Patients
• Increase in Research and Development Activities
• Increasing Market Size

Chronic Spontaneous Urticaria Market Barriers
• Lack of Understanding of Disease Pathology
• Approaching Patent Cliff

Scope of the Chronic Spontaneous Urticaria Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Spontaneous Urticaria Companies: Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly and Company, Genentech, GI Innovation/Yuhan, Regeneron, GlaxoSmithKline, Taiho Pharma, Glenmark Pharmaceuticals, Gossamer Bio, Kiniksa Pharmaceuticals, Mycenax Biotech, Novartis, Regeneron, Synermore Biologics, UCB Biopharma, United BioPharma, and others
• Key Chronic Spontaneous Urticaria Therapies: Ligelizumab, Remibrutinib (LOU064), Tezepelumab, CDX-0159, GI-301, Dupilumab (DUPIXENT), UB-221, MTPS9579A, Lirentelimab (AK002), TAS5315, rilzabrutinib, GDC-0853, AZD1981, Desloratadine, and others
• Chronic Spontaneous Urticaria Therapeutic Assessment: Chronic Spontaneous Urticaria current marketed and Chronic Spontaneous Urticaria emerging therapies
• Chronic Spontaneous Urticaria Market Dynamics: Chronic Spontaneous Urticaria market drivers and Chronic Spontaneous Urticaria market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Spontaneous Urticaria Unmet Needs, KOL's views, Analyst's views, Chronic Spontaneous Urticaria Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.